Business
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
SUMMIT NDA for bezuclastinib in patients with NonAdvSM submitted in December 2025; APEX NDA submission for bezuclastinib in patients with AdvSM on track for 1H 2026PEAK NDA initiated for bezuclastinib in patients with 2L GIST under Real-Time Oncology Review (RTOR) and Breakthrough Therapy Designation (BTD); completion of NDA on track for April 2026Six abstracts from SUMMIT trial of bezuclastinib in patients with NonAdvSM accepted for presentation at 2026 AAAAI annual meetingStrong financial posi
About this update from Cogent Biosciences, Inc.
[{"type":"image","alt":"Cogent Biosciences, Inc.","displaySize":"","headline":null,"caption":"Cogent Biosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":125,"url":"https://media.zenfs.com/en/globenewswire.com/8335c95b9c1a950d92b59f2ace91c141"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qAAHX1MmM2zkyy7g5FdFgQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3NTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8335c95b9c1a950d92b59f2ace91c141","width":300,"height":125}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"SUMMIT NDA for bezuclastinib in patients with NonAdvSM submitted in December 2025; APEX NDA submission for bezuclastinib in patients with AdvSM on track for 1H 2026","length":164,"tagName":"p"}]},{"val":[{"type":"text","content":"PEAK NDA initiated for bezuclastinib in patients with 2L GIST under Real-Time Oncology Review (RTOR) and Breakthrough Therapy Designation (BTD); completion of NDA on track for April 2026","length":186,"tagName":"p"}]},{"val":[{"type":"text","content":"Six abstracts from SUMMIT trial of bezuclastinib in patients with NonAdvSM accepted for presentation at 2026 AAAAI annual meeting","length":129,"tagName":"p"}]},{"val":[{"type":"text","content":"Strong financial position with $901 million sufficient to fund operations into 2028","length":83,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":562,"olType":false},{"type":"text","content":"WALTHAM, Mass. and BOULDER, Colo., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and reported financial results for the fourth quarter and full year of 2025.","length":324,"tagName":"p"},{"type":"text","content":"“Following three positive pivotal trials in 2025, we have entered 2026 with tremendous momentum and multiple value-creating regulatory catalysts underway,” said Andrew Robbins, Cogent’s President and Chief Executive Officer. “We have submitted our SUMMIT NDA for bezuclastinib in patients with NonAdvSM, initiated our PEAK NDA under the FDA’s RTOR program for bezuclastinib in patients with second-line GIST, and remain on track to submit our APEX NDA for bezuclastinib in patients with AdvSM in the first half of this year. These recen...